Skip to main content

Table 1 Baseline characteristics of the study cohort

From: Impact of timing of continuous intravenous anesthetic drug treatment on outcome in refractory status epilepticus

  Total cohort
(n = 77)
Early cIVADs
(n = 53)
Late cIVADs
(n = 24)
P value
Demographics
 Gender, female 47 (61.0) 29 (54.7) 18 (75.0) 0.091
 Age on admission, years 70 (52–76) 70 (49–77) 70 (54–76) 0.830
 Premorbid mRS 2 (0–3) 2 (0–4) 2 (1–4) 0.928
Median STESS and STESS components
 STESS 3 (2–4) 3 (2–5) 2 (1–4) 0.106
 History of seizures 40 (51.9) 25 (47.2) 15 (62.5) 0.212
 Stuporous or comatose on admission 52 (67.5) 41 (77.4) 11 (45.8) 0.006
 Complex partial SE 28 (36.4) 14 (26.4) 14 (58.3) 0.007
 Generalized convulsive SE 34 (44.2) 30 (56.6) 4 (16.7) 0.001
 NCSE in coma 15 (19.5) 9 (17.0) 6 (25.0) 0.535
Etiology
 Acute symptomatic 38 (49.4) 28 (52.8) 10 (41.7) 0.365
 Remote symptomatic 18 (23.4) 11 (20.8) 7 (29.2) 0.419
 Progressive symptomatic 10 (13.0) 5 (9.4) 5 (20.8) 0.270
 Unknown 11 (14.3) 9 (17.0) 2 (8.3) 0.486
 Potentially fatal 35 (45.5) 24 (45.3) 11 (45.8) 0.962
  1. Data are number (percentage) or median (interquartile range)
  2. Abbreviations: cIVAD continuous intravenous anesthetic drug, mRS modified Rankin Scale, NCSE non-convulsive status epilepticus, SE status epilepticus, STESS Status Epilepticus Severity Score